News

  Today marks an important milestone for SBI Canada’s Phase III RCT entitled “Fluorescence Imaging of Carcinoma During Breast Conserving Surgery”, as the first patient surgery was performed successfully at Orlando Health in Orlando, Florida. (ClinicalTrials.gov Identifier: NCT04815083) This trial utilizes the tumor selectivity of 5-ALA combined with the handheld Eagle fluorescence imaging device to enable surgeons to conduct improved intraoperative margin assessment and fluorescence-guided breast conserving surgery. Recruitment of additional clinical trial sites is underway and expected to include 20 surgical centers across Canada and the Unites States, including Princess Margaret Cancer Center.

We would like to congratulate Helen Jin on her acceptance into the University of Western Ontario MD Program, knowing she was also accepted to several other prestigious MD programs across Canada. Helen joined the DaCosta Lab in 2019 to pursue her MSc in the Department of Medical Biophysics, UofT and will be graduating in June 2021. During her time as a devoted member of our team, Helen has spearheaded projects and successful peer-reviewed grants (CIHR, Leukemia and Lymphoma Society, Cancer Research Society) examining leukemia cell biology and potential immunotherapeutic options using a novel murine femur window chamber model to image…

Today, SBI ALApharma Canada Inc., a subsidiary of photonamic GmbH & Co. KG (Pinneberg, Germany), a subsidiary of SBI Holdings, Inc. (Minato-ku, Tokyo) announced it has enrolled the first patient in its Pivotal Phase III randomized controlled trial evaluating the safety and efficacy of PD G 506 A (5-ALA HCl) in margin assessment during breast conserving surgery, after receiving FDA IND clearance for the trial in April. Detailed information can be found here. These achievements mark important steps in SBI Canada’s ongoing clinical investigations into the use of 5-ALA’s tumor selectivity and the novel fully handheld Eagle imaging technology for…

Today, SBI ALApharma Canada Inc., a subsidiary of photonamic GmbH & Co. KG ( Pinneberg, Germany), a subsidiary of SBI Holdings, Inc. (Minato-ku, Tokyo); received FDA Investigational New Drug (IND) clearance for its Pivotal Phase III randomized controlled trial (RCT) evaluating the safety and efficacy of PD G 506 A (5-ALA HCl) in intraoperative margin assessment during breast conserving surgery. This multicenter trial involves over 400 patients across 20 centers across the US and Canada and will use SBI Canada’s patented intraoperative handheld Eagle Fluorescence Imaging SystemTM to visualize 5-ALA-induced protoporphyrin IX (PpIX) fluorescence in real-time in breast cancer tissues during surgery.…